
    
      To evaluate the efficacy and safety of tigecycline to treat complicated intra-abdominal
      infections in hospitalized patients. Both the clinical response profile and the
      microbiological response profile will be assessed. The primary endpoint will be clinical
      response within the microbiological evaluable population at the test-of-cure assessment.
    
  